Share on StockTwits

Gilead Sciences (NASDAQ:GILD) EVP Gregg H. Alton sold 33,000 shares of Gilead Sciences stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $84.12, for a total value of $2,775,960.00. Following the completion of the transaction, the executive vice president now directly owns 126,694 shares in the company, valued at approximately $10,657,499. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Monday. They now have a $75.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, May 29th. Finally, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $135.00 to $142.00 in a research note on Wednesday, May 28th. Two investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $94.91.

Gilead Sciences (NASDAQ:GILD) traded up 0.92% on Thursday, hitting $87.90. The stock had a trading volume of 9,126,111 shares. Gilead Sciences has a 52 week low of $51.63 and a 52 week high of $87.88. The stock has a 50-day moving average of $81.55 and a 200-day moving average of $77.9. The company has a market cap of $135.0 billion and a price-to-earnings ratio of 32.26. Gilead Sciences also was the recipient of a significant drop in short interest during the month of June. As of June 13th, there was short interest totalling 92,230,036 shares, a drop of 2.0% from the May 30th total of 94,135,575 shares. Approximately 6.0% of the shares of the company are short sold. Based on an average daily volume of 10,372,330 shares, the days-to-cover ratio is presently 8.9 days.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $6.28 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.